Cypherpunk Technologies Inc (CYPH) 株価予測

Cypherpunk Technologies, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2017-01-24. The firm focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.